The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known by brand names Ozempic and Wegovy, has the ability to counter metabolic dysfunction-associated steatohepatitis, or MASH, liver disease and some of its risk factors.

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.

Researchers say semaglutide may help reverse MASH, a progressive liver condition affecting millions of Americans.